CYP7A1 and intrahepatic cholestasis: Consistent with their acute effects on C57BL/6J mice, the chronic treatments of FGF19WT and FGF19ΔKLB markedly inhibited hepatic Cyp7a1 mRNA levels (the enzyme that limits the pace of the conventional BAs production pathway) and Cyp27a1 (catalyzing BA biosynthesis in the alternative pathway) in ANIT-induced mouse intrahepatic cholestasis model (Fig. 2E-H).